Financial Survey: Avantor (NYSE:AVTR) & IceCure Medical (NASDAQ:ICCM)

Avantor (NYSE:AVTR) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Avantor and IceCure Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	1	11	3	0	2.13
IceCure Medical	1	1	2	0	2.25

Avantor presently has a consensus price target of $13.60, indicating a potential upside of 15.40%. IceCure Medical has a consensus price target of $2.64, indicating a potential upside of 309.16%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Avantor.

Earnings and Valuation

This table compares Avantor and IceCure Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.78 billion	1.18	$711.50 million	($0.13)	-90.65
IceCure Medical	$3.29 million	13.45	-$15.32 million	($0.26)	-2.48

Avantor has higher revenue and earnings than IceCure Medical. Avantor is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.1% of Avantor shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 1.2% of Avantor shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Avantor and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avantor	-1.25%	10.91%	5.34%
IceCure Medical	-513.95%	-243.68%	-123.94%

Risk & Volatility

Avantor has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Summary

Avantor beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

About Avantor

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.